CAS No. |
23214-92-8 |
中文名称 |
(8S,10S)-10-(((2R,4S,5S,6S)-4-氨基-5-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-7,8,9,10-四氢并四苯-5,12-二酮 |
英文名称 |
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
别名 |
Doxorubicin hydrohloride;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;DOXORUBICIN;10-((3-amino-2,3,6-trideoxy-alpha-l-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;(1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside;ADRIAMYCIN;Adriamycin Adriamycin;(8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione |
标准英文名 |
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
MDL No. |
MFCD00869292 |
分子式 |
C27H29NO11 |
分子量 |
543.17
|
精确分子量 |
543.17
|
SMILES |
OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N |
标准SMILES |
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=C(C=CC=C3C(=O)C1=C2O)OC)C(=O)CO |
用途 |
Doxorubicin hydrochloride is clinically used for the treatment of acute and chronic lymphocytic leukemia, as well as various solid tumors, including lymphoma (Hodgkin’s and non-Hodgkin’s), breast cancer, ovarian cancer, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, Ewing’s sarcoma, Wilms’ tumor, neuroblastoma, gastric cancer, pancreatic cancer, hepatocellular carcinoma, prostate cancer, squamous cell carcinoma of the head and neck, testicular cancer, lung cancer, bladder cancer, medullary thyroid carcinoma, and other sarcomas. It is also effective in patients resistant to daunorubicin. Doxorubicin shows synergistic effects when combined with cytarabine, vincristine, or fluorouracil. |
InChIKey |
AOJJSUZBOXZQNB-TZSSRYMLSA-N |